In the present study, we conducted two separate indirect comparisons to assess the efficacy of the two NMPA-approved next-generation BTK inhibitors zanubrutinib and orelabrutinib in the treatment of R/R CLL/SLL or R/R MCL patient based on Chinese populations. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.